BrightGene expands pipeline, invests in innovation and strategic partnerships

** BrightGene Bio-Medical Technology (SSE:688166) has released its 2024 Annual Report Summary, highlighting a year of strategic advancements and a focus on innovation. The company is continuing its development of a pipeline with an additional investment in early-stage pharmaceutical and medical device projects through its participation in the Nanjing Ruihong Weitai Venture Capital Fund (for RMB 20 million). This investment is intended to accelerate the company's reach into the early-stage pharmaceutical and medical device fields and the forefront of life science innovation to create potential synergies with the company's research and development.